MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

Genaera

Status and phase: Terminated; Phase 2

Conditions: Macular Degeneration

Treatments: Drug: MSI-1256F (Squalamine Lactate)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00094120

MSI-1256F-208

Details and patient eligibility

About

Age-Related Macular Degeneration (AMD) is a degenerative disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula.

Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with "wet" AMD.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of "wet" age-related macular degeneration

Exclusion criteria

• Prior treatment for "wet" age-related macular degeneration

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind